All In Biotech

NDA 217180 · Incyte Corp

Jakafi Xr

Ruxolitinib Phosphate · Oral · Kinase Inhibitor; Janus Kinase Inhibitor

Orphan

Last checked: Nov 20, 2026Latest source record: Jul 20, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2026

May 1, 2026

Approved uses

1

Original approval plus efficacy supplements

Registered trials

453

74 Phase 3, 109 recruiting

FAERS reports

10,697

10,364 serious, 2,687 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jul 20, 2026.

JAKAFI/JAKAFI XR is a kinase inhibitor indicated for treatment of: intermediate or high-risk myelofibrosis, including primary myelofibrosis, post-polycythemia vera myelofibrosis, and post-essential thrombocythemia myelofibrosis in adults. ( 1.1 ) polycythemia vera in adults who have had an inadequate response to or are intolerant of hydroxyurea. ( 1.2 ) steroid-refractory acute graft-versus-host disease in adult and pediatric patients 12 years and older. ( 1.3 ) chronic graft-versus-host disease after failure of one or two lines of systemic therapy in adult and pediatric patients 12 years and older. ( 1.4 ) 1.1 Myelofibrosis JAKAFI/JAKAFI XR is indicated for treatment of intermediate or high-risk myelofibrosis (MF), including primary MF, post-polycythemia vera MF, and post-essential thrombocythemia MF in adults. 1.2 Polycythemia Vera JAKAFI/JAKAFI XR is indicated for treatment of polycythemia vera (PV) in adults who have had an inadequate response to or are intolerant of hydroxyurea. 1.3 Acute Graft-Versus-Host Disease JAKAFI/JAKAFI XR is indicated for treatment of steroid-refractory acute graft-versus-host disease (aGVHD) in adult and pediatric patients 12 years and older. 1.4 Chronic Graft-Versus-Host Disease JAKAFI/JAKAFI XR is indicated for treatment of chronic graft-versus-host disease (cGVHD) after failure of one or two lines of systemic therapy in adult and pediatric patients 12 years and older.

Mechanism: Ruxolitinib, a kinase inhibitor, inhibits Janus Associated Kinases (JAKs), JAK1 and JAK2, which mediate the signaling of a number of cytokines and growth factors that are important for hematopoiesis and immune function. JAK signaling involves recruitment of STATs (signal transducers and activators of transcription) to cytokine receptors, activation, and subsequent localization of STATs to the nucleus leading to modulation of gene expression. MF and PV are myeloproliferative neoplasms (MPNs) known to be associated with dysregulated JAK1 and JAK2 signaling. In a mouse model of...

Therapeutic areas: Oncology · Immunology and inflammation

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • May 1, 2026 Original approval · Type 5 - New Formulation or New Manufacturer OrphanLetterLabel
5 products under this application
  • JAKAFI XR · RUXOLITINIB PHOSPHATE EQ 44MG BASE · TABLET, EXTENDED RELEASE, ORAL · Prescription
  • JAKAFI XR · RUXOLITINIB PHOSPHATE EQ 22MG BASE · TABLET, EXTENDED RELEASE, ORAL · Prescription
  • JAKAFI XR · RUXOLITINIB PHOSPHATE EQ 55MG BASE · TABLET, EXTENDED RELEASE, ORAL · Prescription
  • JAKAFI XR · RUXOLITINIB PHOSPHATE EQ 33MG BASE · TABLET, EXTENDED RELEASE, ORAL · Prescription
  • JAKAFI XR · RUXOLITINIB PHOSPHATE EQ 11MG BASE · TABLET, EXTENDED RELEASE, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Ruxolitinib" as an intervention, any sponsor and status, largest first.

All 453 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • off label use1,418
  • drug ineffective1,035
  • death787
  • product use in unapproved indication781
  • anaemia738
  • pyrexia597
  • pneumonia578
  • thrombocytopenia562
  • platelet count decreased532
  • haemoglobin decreased511
  • febrile neutropenia458
  • splenomegaly446

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
201211
201314
201422
201553
2016103
2017209
2018299
2019333
2020528
20211,104
20221,650
20231,844
20241,599
20251,653
20261,275

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 398 on PubMed

Sponsor: Incyte

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.